List of Therapeutic Companies in Italy - 44

Adamas Biotech is a clinical stage company pioneering the development of nutraceutical-based prophylactic and therapeutic solutions for a range of clinical and wellness indications. The company is specialized in the development of bioactive molecules derived from botanicals, in particular, green tea catechins. Its initial pipeline is based on 100% natural formulations of green tea purified compounds, which are under development for use in cancer prevention, anti-aging, wound care and sports medicine.

Alia Therapeutics is a pioneering gene editing company with a vision to revolutionize medicine by curing genetic diseases at their roots. Alia’s versatile portfolio of novel CRISPR systems expands the range of targetable genomic sites and increases the precision of genetic modifications, bringing gene editing to the next level of specificity and safety, which are required for therapeutic applications.

Altheia Science is a pioneering start-up founded by two world renowned Italian scientists, Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with AurorA-TT. Altheia Science’s pipeline exploits pioneering therapeutic tools for autoimmune diseases and cancer. The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments. This can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients’ hematopoietic stem cells. Altheia Science’s approach intends to drastically modify the natural history of diseases with high clinical impact in autoimmunity and cancer by modulating PD-L1 expression, achieving tangible and durable benefit for each patient.

At Angelini Pharma, we work every day to grow as a leading Pharma Company that makes a difference in patients' life. Since 1919. We aim at becoming a leading European player, offering people, patients and their beloved ones new medicines and solutions to achieve better health outcomes and higher quality of life. We make our vision real through robust pipeline growth, strong collaborations with best-in-class Research Institutes and valuable partnerships with our strategic allies. We pledge to successfully develop distinctive treatments for CNS and Mental Health disorders while preserving our leading position in the Consumer Health segment. Angelini Pharma is part of Angelini Industries. Social media privacy notice: https://bit.ly/socialmediaprivacynotice

Reprogramming DNA methylation in disease conditions by RNA therapeutics APTADIR Contact us NEWS Press Release Reprogramming DNA methylation by RNA therapeutics A novel therapeutic approach for untreatable cancers and rare diseases Aberrant methylation by DNA methyltransferase 1 (DNMT1) of certain genes may cause abnormal cell development and lead to disease. Current therapies targeted to inhibit

BetaGlue Therapeutics is a clinical stage oncology company that has developed an advanced radiotherapy platform enabling localised targeted treatment of both unresectable solid tumours and also treatment of surgical resection margins called YntraDose.

BIOGENERA SpA is a company operating in the biotechnology pharmaceutical sector, specialising in the research and development of new DNA-based patient-specific biotechnological medicines for the treatment of serious pathologies. Founded in 2008, with its headquarters in Bologna, BIOGENERA SpA has a multidisciplinary team of researchers and is supported by numerous University partnerships ( in particular, the University of Bologna) and other companies of the pharmaceutical sector.

BiOMViS Srl is a Biotech Company committed to foster prophylactic and immunotherapeutic interventions in infectious diseases and cancer.

Borea Therapeutics develops next-generation gene therapy vectors using a knowledge-based capsid design platform

CaSRevolution is a drug discovery company developing innovative therapies for neurodegenerative diseases.

Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization cancer immunotherapies, cell therapies and cell-based biotherapeutics. Our goal is to support the development of novel cancer immunotherapies by accelerating the R&D, advancing the quality control and monitoring the clinical response to these treatments. Through the use of proprietary microfluidic technologies, highly-automated analytical instruments and AI-powered image and data analytics, the Cellply platform defines the function of the immune system one cell at a time, combining functional data with other multiplex data and providing an unprecedented single-cell analytical solution.

Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making.  As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

Contraria Biotech (formerly AchilleS Vaccines) is a biopharmaceutical development company that aims to create sustainable therapeutic and prophylactic drugs against infectious diseases. We are committed to designing innovative, cost-effective therapeutic and prophylactic products to address some of today's major global health problems, including antibiotic resistance, emerging diseases and pandemics.

Diatech Pharmacogenetics, the leading Italian Precision Medicine company. Diatech Pharmacogenetics is a provider of molecular diagnostic tools for precision medicine. The company aims at simplifying complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acids extraction and their molecular analysis, to final reporting. The company has 10 years of experience in the successful implementation of several nucleic acid analysis technologies into regulated diagnostic pipelines; examples include pyrosequencing, mass spectrometry and digital molecular barcoding. Leading cancer centres in Italy and abroad rely on Diatech CE-IVD solutions to extract nucleic acids from patient samples, analyse them with the most advanced technologies and interpret them with the latest bioinformatic algorithms. Excellence in each step of the diagnostic pipeline results in the personalisation of treatments, increased drug efficacy, reduced side-effects and ultimately better patient outcomes.

Dompé farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up. We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 160,000 square meter R&D and production site in L’Aquila, Italy, is the heart of Dompé. Here, we conduct vital research, and produce and distribute our primary care and biotech products. Primary Care includes a broad spectrum of over-the-counter treatment solutions, prescription medications, supplements and medical devices. Our Biotech focuses on the development of treatments for rare diseases. The main therapeutic areas include pain relief, inflammation, ophthalmology, diabetes care, nutrition and oncology. In the pursuit of improving human health, our R&D strives to break through in unconventional places. This is what led us to Nerve Growth Factor (NGF), a Nobel Prize-winning discovery made in 1986. We leveraged 50 years of research to transform this discovery into a breakthrough treatment. Our human recombinant NGF, cenegermin, is the first treatment for a rare degenerative eye disease, neurotrophic keratitis. That deep appreciation of science keeps us committed to investigating neurotrophins. Our relentless pursuit in identifying new treatments for diseases allowed us to harness the potential of bioinformatics to accelerate the drug discovery process. The result is Exscalate, a structure-based virtual screening platform developed in-house and currently one of the most powerful supercomputing and artificial intelligence platforms for drug testing. We are focused on the road ahead. Our hunger to deliver what patients need from science keeps us focused on what matters. We embrace the challenge in science.

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

Etna Biotech srl - Zydus Cadila Research Center is a company based out of Italy.

Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment. Genenta’s lead product candidate, Temferon™, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

Genespire is a biotechnology company focused on the development of durable and transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners.

Heqet Therapeutics is a company that develops groundbreaking genetic medicines to reverse the damage of ischemic heart disease, the leading cause of death worldwide. Their therapeutic approach aims to address the underlying drivers of heart disease.

Holostem Terapie Avanzate is the first biotechnological company entirely devoted to development, manufacture, registration and distribution of Advanced Therapies Medicinal Products (ATMPs) based on cultures of epithelial stem cells both for cell and gene therapy. The main aim of Holostem Terapie Avanzate is to promote epithelial stem cell-based Regenerative Medicine for patients with no alternative therapeutic solutions. Holostem Terapie Avanzate is located into the Centre for Regenerative Medicine "Stefano Ferrari"​ of the University of Modena and Reggio Emilia

IAMA Therapeutics is a late preclinical-stage pharmaceutical company raising a Series B to fund the clinical development of its lead candidate in epilepsy and neurodevelopment disorders. The Company’s lead candidate, IAMA-6, is a "best-in-class" selective NKCC1 inhibitor being developed for various orphan brain disorders, including drug-resistant epilepsy, and is expected to enter the clinic in October 2023. Other pipeline candidates include new molecular entities to target Cation Chloride Cotransporters in pediatric neuropsychiatric conditions.

The International Centre for Genetic Engineering and Biotechnology ICGEB is an intergovernmental research organisation that operates within the United Nations common system. It was established in 1983 as a Centre for excellence in research, training and technology transfer to industry in the field of biotechnology to promote sustainable global development. With over 60 Member States and 40 Affiliated Centres worldwide, it runs 46 research programmes in its own laboratories in Trieste, Italy, New Delhi, India and Cape Town, South Africa. Almost 700 people work at ICGEB comprising 550 scientific personnel. The organisation has generated almost 3000 scientific publications in the Life Sciences since 1988 and currently holds over 80 active research grants. ICGEB has awarded almost 1400 fellowships, with over 300 fellows and 150 PhD students currently on board. It has organised over 560 Meetings and Courses worldwide and has funded over 550 Collaborative Research Programme-Research Grants. It has produced and distributed over 600 movies (podcasts) of high-scientific content in 50 topics in the Life Sciences - that are freely available for download on iTunes, YouTube and on the ICGEB Web site. Active in Public Engagement and on Social Media networks, ICGEB invites, in particular, its Alumni to join the ICGEB Alumni Group on Linkedin. http://www.icgeb.org

Kither Biotech is a biopharmaceutical company that develops novel therapies for the treatment of rare pulmonary diseases with an high unmet medical need. Our first two product candidates KIT2014 and KITCL27, focus on cystic fibrosis and idiopathic pulmonary fibrosis respectively.

Lead Discovery Siena - LDS - is an innovative SME focused on the research for new drugs. LDS offers pharmaceutical services for Industry and Academia and has a diversified pipeline of in licensed and proprietary products for oncology and infections therapeutic areas, including rare diseases. LDS was founded as a spin-off of the University of Siena in 2012 by combining the scientific background and the entrepreneurship of its management to offer specific competences and solutions in drug discovery. LDS capitalizes on the wide scientific expertise in pharmacology and medicinal chemistry to efficiently expedite the discovery and development of small molecule medicines. A number of molecules have been successfully advanced by LDS team as evidenced by publications and patents, and several goals achieved in the course of collaborations which earned us the trust of our customers. LDS actively participates to national and international projects, with a special attention to local synergies at industrial and academic level within the Life Science area. LDS laboratories are located in the Toscana Life Sciences facilities (www.toscanalifesciences.org), a non-profit organization supporting research activities and promoting the creation of innovative companies in Life Sciences.

Lo.Li. Pharma INTERNATIONAL is a branch of Lo.Li. Pharma Srl, a growing pharmaceutical company, based in Rome, dedicated to the research, development and out-licencing distribution of Medical Devices and Functional Dietary Supplements. The company's key success factor is the continuous effort in developing new products while responding to the needs of patients and of new treatments and prevention tools for the medical class. The innovative formulations of Lo.Li. Pharma have attracted the attention of many foreign Companies and private citizens alike, all looking forward to have Loli's products available in their own countries. With more than 20 products in our portfolio and our brand presented in more than 50 countries, we are always seeking out-licensing opportunities with key strategic partners for long term exclusive distribution. For further information, kindly contact us at info@lolipharmainternational.com or call +39 06.88379670

MediaPharma Srl is a preclinical stage biotech company focusing on research and development of monoclonal antibodies, Antibody-Drug Conjugates (ADCs) and other products for the treatment of cancer and other severe diseases with high unmet medical needs. At MediaPharma, scientists, doctors and entrepreneurs share the same values and have been working together for years.

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of €4,155 million and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 578 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world.

At Microbion, we are developing a new class of therapeutic drugs to tackle the unmet needs of rare, chronic, and serious diseases. Our lead drug candidate, pravibismane, is a first-in-class therapeutic with a novel triad of activities: anti-infective, antibiofilm, and anti-inflammatory. These synergistic properties uniquely position pravibismane to address conditions where conventional treatments often fail. We are advancing multiple pravibismane formulations through clinical development, focusing on indications with significant unmet needs: - Topical pravibismane for diabetic foot ulcers/infections: Phase 3 studies planned for 2025 - Local/surgical pravibismane for orthopedic infections: Phase 2a studies completed - Inhaled pravibismane for pulmonary diseases including Nontuberculous mycobacteria lung infections: Ready for first-in-human Phase 1 studies Pravibismane has been granted FDA Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations, underscoring its disruptive potential. To date, pravibismane development has been supported by over $22M in grants awarded from leading organizations, including the U.S. Department of Defense, NIH, CARB-X, and the Cystic Fibrosis Foundation. We are actively seeking strategic licensing and development partners to advance Phase 3 trials, explore new indications (e.g., immunomodulation and inflammation), and bring pravibismane to patients worldwide.

NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics. The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes. NanoPhoria's lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.

Nerviano Medical Sciences S.r.l. (NMS Srl) focuses on discovering and clinically developing small molecule NCEs for oncology, aiming to deliver first- and best-in-class personalized cancer treatments through innovative mechanisms and novel drug targets. Our pipeline, built from our validated kinase platform, includes projects from early preclinical to clinical stages, advanced both internally and in partnership.  NMS Srl combines biotech agility with big pharma quality, guided by an experienced management team and a skilled staff with global expertise in research, drug discovery, and clinical development. Our capabilities are extended by NMS Group affiliates Accelera (AdMet) and NerPharMa (manufacturing), covering the entire drug development process. A core strength lies in our renowned kinase inhibitor platform, featuring an extensive chemical library and IP coverage, which has led to successful out-licensing deals, including with encorafenib and entrectinib. Additionally, we are advancing a PARP-family-focused platform to discover NCEs targeting NAD-binding pockets, with potential expansion to other NAD-dependent enzymes. Our growing payload-linker platform further enhances our pipeline by enabling next-generation ADC production. Collaborating globally with academic, clinical, and industry partners, we seek further strategic alliances to develop, commercialize, and expand our product portfolio while exploring in-licensing opportunities for promising clinical assets.

Building Brain Computers Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca'​ Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics and biotechnologies.

Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders. Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization. Xadago® (safinamide) has received marketing authorization for the treatment of Parkinson’s disease in the European Union and Switzerland (both 2015) as well as in the U.S. (2017) and is commercialized in Europe by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the US. Valeo Pharma holds the commercialization rights for the Canadian market, Seqirus for Australia & New Zealand, and Medison for Israel. Meiji Seika, in collaboration with Eisai, has the rights to develop and commercialize the compound in Japan and other key Asian territories. In addition to Xadago® for Parkinson’s disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indications. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. The Company is listed on the SIX Swiss Exchange, under the trading symbol NWRN, on the primary market of the Düsseldorf Stock Exchange and on XETRA, trading symbol NP5.

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients. At present, Philogen has four promising anti-cancer antibody derivatives and an antibody derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies are in planning. Our Zurich-based daughter company Philochem serving as the R&D unit isolates the most promising candidate products, while in Siena (Italy) the pharmaceuticals are produced according to GMP standards and advanced to clinical trials. Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents.

Probiotical is an Italian family-owned company specialized since 1985 in probiotics manufacture, from the raw material to the finished products, with very high quality, guaranteed stability and scientifically backed strains. We are driving innovation in a variety of functionalities and technologies. We offer our customers wide opportunities of customization and range extensions for probiotic blends and finished products ready-to-market, either under Probiotical's brand or in private label.

Recordati has been at the forefront of life-enhancing and life-changing medicines for almost 100 years. With its beginnings in a family run pharmacy in Correggio, Italy in the 1920s, Recordati is now a global pharmaceutical force, listed on the Italian stock exchange, with over 4,300 employees. We are a group of like-minded, passionate individuals who go to extraordinary lengths for our partners, customers, investors and the people across the globe who we serve. We develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries. At Recordati, our mantra is simple. We’ve always believed that health, and the opportunity to live life to the fullest, is a right, not a privilege. Whether that is for common diseases or the rarest – we want to give people the opportunity to be the best version of themselves. This drive will never stop. Together, we will always be reimagining tomorrow – with new ideas, new technologies and new innovations to fight diseases. Recordati. Unlocking the full potential of life.

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

Discovering and developing novel drugs has been our passion, work and mission for over 50 years. Rottapharm Biotech lives for innovation and innovation lives at Rottapharm Biotech. This is all we are and all we want to be.

Sibylla is an innovative start-up founded in 2017 as a spin-OFF of the INFN (National Institute of Nuclear Physics) and the Trento and Perugia Universities. Its multidisciplinary team of co-founders has developed a pioneering Early Drug Discovery method that applies to the research and design of new drugs, effective against diseases so far incurable. Drug discovery is an extremely complex problem, therefore requiring innovation. Sibylla is a beautiful example of how innovation can be pushed forward by a multidisciplinary and agile team. Sibylla's approach is based on the possibility of simulating the folding pathway from the amino acid sequence as produced by the cells' ribosomes to the native state. Traditional pharmacological methods investigate the target proteins' interaction sites in their native, biologically active state. Novel methods act at the DNA level. Sibylla follows an alternative approach. We identify small molecules that bind to pockets found in the intermediate folding state. These pockets disappear in the native state, and that is why we may try to drug proteins which have been so far considered undruggable. Sibylla technology is called PPI-FIT (Pharmacological Protein Inactivation by Folding Intermediate Targeting). A molecule found through PPI-FIT would impair the folding of the protein, leading it to degradation. The overall effect is a selective reduction of the expression level of the target protein. The medical areas focused on by Sibylla's research include oncology and antibiotic resistance, although the technology can be applied to any therapeutic area. The company is developing a proprietary pipeline of potential drugs. We can also provide co-development or identifying potential drugs for pharmaceutical companies' specific targets. We recently signed a collaboration agreement with an important Pharma company. Besides the promising results already achieved, Sibylla keeps being engaged in developing proprietary computing technology.

StemGen is a clinical stage biotech company developing innovative differentiation biotherapies for cancer. StemGen is also involved in research on neural stem cells.

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity. For this purpose, Takis offers cutting-edge technologies and works with the idea that new cancer treatment must be based on in-depth knowledge of tumour biology and the concept of personalized cancer therapy. Together with some of its partners, Takis is involved in the identification of new biomarkers and in the development of molecular diagnostic tests. The main competence of Takis’ researchers is the delivery of genes in vivo through numerous technologies. The foremost one is the electric transfer of genes (gene-electro-transfer–EGT) on which we have more than ten years experience. This technology can significantly increase the tissue uptake of nucleic acids in vivo, such as skeletal muscle, or the tumor itself, with a functional enhancement that leads to relevant immunological and antitumoral effects. In this regard, In addition to its research pipeline, Takis is engaged with academic and industrial partners in research aimed at studying the effectiveness of innovative drugs in biological systems or develop diagnostic tests based on the detection of new biomarkers. Takis offers itself as partner of choice because of its efficiency, speed of execution and low operating costs.

Ulisse BioMed is a healthcare biotech company operating in diagnostics, theranostics and therapeutics with the mission to develop innovative solutions in these fields. Ulisse BioMed has three proprietary technology platforms capable of generating innovative and competitive products: Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). Ulisse BioMed owns a portfolio of intellectual properties made of 8 international patent applications that cover the three technology platforms (3 related to Sagitta, 2 related to NanoHybrid, 1 related to Aptavir and 2 transversal to the three platforms), two of them are granted in Italy and in Europe.

ViroStatics srl is a privately held bio-pharmaceutical company, headquartered in Sassari (Italy), with a successful history of fundraising and a large international network of partners and collaborators. Management has track record in Licensing and M&As. Its key operational field is oncology. Over the years, ViroStatics has developed a robust pipeline of proprietary compounds for several distinct disease indications (with initial focus on Breast cancer resistant to CDK4/6 inhibitors and Mesothelioma), all of them covered by patent protection towards 2039, characterized by their unique kinase selectivity, efficacy and safety profiles. ViroStatics is also still active in virology offering services to test drugs and devices against SARS-CoV-2. The company is led by a top-level team, with experience in the conduction of complex projects. Its expertise spans from basic science to clinical trials with over 100 published manuscripts and over 10 clinical trials coordinated (Phase I and Phase II). http://www.virostatics.com/

Zambon is a modern healthcare company founded on the history and values of an Italian family and committed to innovating cure & care to improve patients’ lives. Zambon is present in three different Continents – Europe, America and Asia – with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon SpA, the pharma subsidiary of the group with its 23 branches, has taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB. In recent years, ZBiotech, a specialized biotech company that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through through the scouting, acquisition, licensing and development of new molecules, has also been established. Zambon produces high quality products thanks to the management of the whole production chain which involves Zach-Zambon Chemicals, a privileged partner for API, custom synthesis and generic products. Zambon complements the offering of medicines with modern health solutions, in order to translate its Vision into concrete actions. Zcube - Zambon Research Venture - is actively scouting for modern health solutions in the field of drug delivery systems, medical devices, biomarkers, diagnostics, digital health and big data solutions. In 2018 Zcube established Careapt, a new start-up which develops integrated Hi-Tech/Hi-Touch solutions for chronic disease management. The group also includes ItaliAssistenza, a Home Care Company involved in Patient Support Programs and home care. Zambon was established in 1906 in Vicenza and is headquartered in Milan within OpenZone, the scientific campus where knowledge is shared between partners in the field of Healthcare, founded with the aim to transform research into enterprise.